"Novartis stock plummets after Entresto patent claim ruled invalid"
Novartis, a pharmaceutical company, experienced a drop in its stock price after losing a patent ruling related to its heart failure drug, Entresto. The court found the claims of the patent to be invalid, leading to concerns about potential generic versions of the drug. Entresto accounted for a significant portion of Novartis' global sales, and the company plans to appeal the ruling. Despite the setback, Novartis maintained its mid-term sales growth outlook and expressed confidence in its future performance.
